Dr Roger Liang
Senior Lecturer
School of Biomedical Sciences and Pharmacy (Pharmacy and Experimental Pharmacology)
- Email:roger.liang@newcastle.edu.au
- Phone:(02) 4985 4959
Career Summary
Biography
Dr Liang was trained as a pharmaceutical scientist and has since developed well-equipped research capabilities and leadership in the cross-disciplinary field of advanced drug delivery and nanomedicine. Dr. Liang completed his PhD in Pharmacy from the University of Queensland. His doctoral research theme was to develop nanoparticulate delivery systems for subunit vaccines, which spanned a range of fields including medicinal chemistry, pharmaceutical formulation, and immunology. Toward the end of his PhD, Dr Liang started to engage in research at the interface between polymer science and drug delivery and had gained hands-on experience in a variety of polymerisation and bioconjugation techniques. Upon completion of PhD, Dr Liang took up a postdoctoral position at UQ to investigate the biological interactions and toxicity of precisely engineered nanoparticles. This research had led to some key fundamental discoveries that resulted in several publications in the premium journals including ACS Nano, Nature Nanotechnology, Nanomedicines etc. During this time, Dr Liang was also a research teaching academic at School of Pharmacy and committed to teaching pharmacy undergraduates. After that, Dr Liang joined the Centre for Advanced Macromolecular Design in University of New South Wales, and his research was to develop a platform technology for the efficient delivery of albendazole towards better anti-cancer treatment. In 2011, Dr Liang accepted a lecturer position to establish drug delivery research group at the School of Biomedical Science and Pharmacy in University of Newcastle.
Research Expertise
Dr Liang’s current research centres on advanced drug delivery and nanomedicine, which are at the interface of multidisciplinary fields including chemical & molecular engineering, materials science, chemistry, biotechnology and medicine. His research mainly involves developing novel biomaterials, utilizing self-assembly strategies to formulate biomaterials into desired nano-, micro- and macroscopic structures, and studying applications of these engineered structures for disease treatment and diagnosis.
Teaching Expertise
I mainly teach into pharmaceutics and pharmacy practice within Master of Pharmacy program. In addition, I also deliver guest lectures into Bachelor of Biomedical Science program in the field of drug delivery.
Qualifications
- PhD, University of Queensland
Keywords
- Biomaterials
- Drug delivery
- Nanomedicine
- Pharmaceutics
- Pharmacy Practice
Professional Experience
UON Appointment
| Title | Organisation / Department |
|---|---|
| Senior Lecturer | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Journal article (26 outputs)
| Year | Citation | Altmetrics | Link | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017 |
Shargh VH, Hondermarck H, Liang M, 'Gelatin-albumin hybrid nanoparticles as matrix metalloproteinases-degradable delivery systems for breast cancer therapy', Nanomedicine, 12 977-989 (2017) [C1] © 2017 Future Medicine Ltd. Aim: To develop matrix metalloproteinase-responsive gelatin-albumin hybrid nanoparticles encapsulating a selective tropomyosin receptor kinase A (TrkA)... [more] © 2017 Future Medicine Ltd. Aim: To develop matrix metalloproteinase-responsive gelatin-albumin hybrid nanoparticles encapsulating a selective tropomyosin receptor kinase A (TrkA) inhibitor GNF-5837 (Gel-Alb-GNF HNPs) and to demonstrate their anticancer effects in breast cancer. Methods: Gel-Alb-GNF HNPs were prepared using a pH-controlled complexation process from cationic gelatin, dextran sulfate and albumin-bound GNF-5837. The anticancer activities of Gel-Alb-GNF HNPs were tested in a panel of subtype-specific breast cancer cell lines. Results: Gel-Alb-GNF HNPs (~130 nm) displayed excellent stability and matrix metalloproteinase-triggered drug release. Compared with GNF-5837 alone, Gel-Alb-GNF HNPs not only significantly enhanced the antiproliferative and anti-invasive effects but also restored the apoptosis of cancer cells. Conclusion: Gel-Alb-GNF HNPs may be adaptable for stand-alone therapies or used in combination with traditional chemotherapies for breast cancer treatment.
|
||||||||||
| 2016 |
Shargh VH, Hondermarck H, Liang M, 'Antibody-targeted biodegradable nanoparticles for cancer therapy', Nanomedicine, 11 63-79 (2016) [C1] © 2016 Future Medicine Ltd. The use of nanotechnology has great potentials to revolutionize the future cancer diagnosis and therapy. In this context, various nanoparticles (NPs) h... [more] © 2016 Future Medicine Ltd. The use of nanotechnology has great potentials to revolutionize the future cancer diagnosis and therapy. In this context, various nanoparticles (NPs) have been developed for targeted delivery of diagnostic/therapeutic agents to the tumor sites, which thus result in greater efficacy and much less side effects. The targeting property of NPs is often achieved by functionalizing their surface with tumor-specific ligands, such as antibodies, peptides, small molecules and oligonucleotides. In this review, we will discuss recent progress in the multifunctional design of antibody-targeted NPs with a special focus on liposomal, polymeric and protein-based delivery systems.
|
||||||||||
| 2016 |
Shargh VH, Hondermarck H, Liang M, 'Albumin hybrid nanoparticles loaded with tyrosine kinase A inhibitor GNF-5837 for targeted inhibition of breast cancer cell growth and invasion.', Int J Pharm, 515 527-534 (2016) [C1]
|
||||||||||
| 2015 |
Noorani L, Stenzel M, Liang R, Pourgholami MH, Morris DL, 'Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model', Journal of Nanobiotechnology, 13 (2015) [C1]
|
||||||||||
| 2014 |
Jiang Y, Liang M, Svejkar D, Hart-Smith G, Lu H, Scarano W, Stenzel MH, 'Albumin-micelles via a one-pot technology platform for the delivery of drugs', Chemical Communications, 50 6394-6394 (2014) [C1]
|
||||||||||
| 2014 |
Noorani L, Pourgholami MH, Liang M, Morris DL, Stenzel M, 'Albendazole loaded albumin nanoparticles for ovarian cancer therapy', European Journal of Nanomedicine, 6 227-236 (2014) [C1] © 2014 by De Gruyter 2014. Albendazole (ABZ), a well-established antiparasitic drug, has been shown to suppress tumor growth in a number of preclinical models of cancer. However, ... [more] © 2014 by De Gruyter 2014. Albendazole (ABZ), a well-established antiparasitic drug, has been shown to suppress tumor growth in a number of preclinical models of cancer. However, the low solubility of ABZ limits its use as a systemic anticancer agent. To enable systemic administration, we have formulated ABZ into albumin nanoparticles with a size range of 200-300 nm, which were cross-linked with glutaraldehyde to stabilize the nanoparticles and to introduce pH-responsive features. Drug release studies demonstrated that about 20% of ABZ was released at neutral pH within a week in comparison to 70% at slightly acidic condition (pH 5). Cellular uptake studies using ovarian cancer cells indicated that nanoparticles were internalized efficiently within 1 h of incubation. Further, cell proliferation results demonstrated that albumin nanoparticles alone showed no cytotoxicity to both normal and cancer cells. In contrast, the drug-loaded nanoparticles exhibited cellular toxicity and high killing efficacy to cancer cells compared to normal cells. Collectively, our results suggest that these albumin nanoparticles may hold great potentials as ABZ carriers for cancer therapy.
|
||||||||||
| Show 23 more journal articles | |||||||||||
Conference (5 outputs)
| Year | Citation | Altmetrics | Link | |||||
|---|---|---|---|---|---|---|---|---|
| 2015 |
Shargh VH, Hondermarck H, Liang M, 'ENHANCING THE EFFICACY OF TYROSINE KINASE INHIBITORS THROUGH BIO-POLYMERIC ALBUMIN HYBRID NANOPARTICLES IN BREAST CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
| 2014 |
Xu B, Wang H, Liang M, Yu C, Hu J, Cheng H, 'A detail enhancement and dynamic range adjustment algorithm for high dynamic range images', Proceedings of SPIE - The International Society for Optical Engineering (2014) © 2014 SPIE. Although high dynamic range (HDR) images contain large amounts of information, they have weak texture and low contrast. What's more, these images are difficult t... [more] © 2014 SPIE. Although high dynamic range (HDR) images contain large amounts of information, they have weak texture and low contrast. What's more, these images are difficult to be reproduced on low dynamic range displaying mediums. If much more information is to be acquired when these images are displayed on PCs, some specific transforms, such as compressing the dynamic range, enhancing the portions of little difference in original contrast and highlighting the texture details on the premise of keeping the parts of large contrast, are needed. To this ends, a multi-scale guided filter enhancement algorithm which derives from the single-scale guided filter based on the analysis of non-physical model is proposed in this paper. Firstly, this algorithm decomposes the original HDR images into base image and detail images of different scales, and then it adaptively selects a transform function which acts on the enhanced detail images and original images. By comparing the treatment effects of HDR images and low dynamic range (LDR) images of different scene features, it proves that this algorithm, on the basis of maintaining the hierarchy and texture details of images, not only improves the contrast and enhances the details of images, but also adjusts the dynamic range well. Thus, it is much suitable for human observation or analytical processing of machines.
|
|||||||
| 2014 |
Shargh VH, Hondermarck H, Liang M, 'MULTIFUNCTIONAL NANOMEDICINES BASED ON ALBUMIN FOR TARGETED BREAST CANCER THERAPY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
|||||||
| Show 2 more conferences | ||||||||
Other (7 outputs)
| Year | Citation | Altmetrics | Link |
|---|---|---|---|
| 2016 | Liang M, 'Enhanced anticancer activity of tyrosine kinase inhibitor GNF-5837 via tumor responsive gelatinalbumin hybrid nanoparticles', (2016) [O1] | ||
| 2015 | Liang M, 'Albumin-dextran-chitosan hybrid nanoparticle enhances the efficacy of tyrosine kinase inhibitor GNF-5837 in breast cancer', (2015) [O1] | ||
| 2015 | Liang M, 'Albumin based nanoparticles can increase the efficiency of Trk inhibitor GNF-5837 in breast cancer', (2015) [O1] | ||
| Show 4 more others | |||
Grants and Funding
Summary
| Number of grants | 7 |
|---|---|
| Total funding | $245,864 |
Click on a grant title below to expand the full details for that specific grant.
20181 grants / $28,000
Therapeutic Targeting of Long Noncoding RNA REG1CP for Colorectal Cancer Treatment$28,000
Funding body: Hunter Medical Research Institute
| Funding body | Hunter Medical Research Institute |
|---|---|
| Project Team | Doctor Roger Liang, Doctor Lei Jin, Professor Xu Dong Zhang |
| Scheme | Project Grant |
| Role | Lead |
| Funding Start | 2018 |
| Funding Finish | 2018 |
| GNo | G1801350 |
| Type Of Funding | C3120 - Aust Philanthropy |
| Category | 3120 |
| UON | Y |
20172 grants / $140,364
Novel epithelial targets and targeting strategies to prevent asthma exacerbations$136,364
Funding body: Asthma Australia
| Funding body | Asthma Australia |
|---|---|
| Project Team | Associate Professor Nathan Bartlett, Conjoint Professor Peter Wark, Doctor Roger Liang, Professor Darryl Knight |
| Scheme | National Research Program |
| Role | Investigator |
| Funding Start | 2017 |
| Funding Finish | 2018 |
| GNo | G1601217 |
| Type Of Funding | C3111 - Aust For profit |
| Category | 3111 |
| UON | Y |
Nanoparticle-mediated mitochondrial delivery of antioxidants for asthma therapy$4,000
Funding body: Faculty of Health and Medicine, University of Newcastle
| Funding body | Faculty of Health and Medicine, University of Newcastle |
|---|---|
| Project Team | Dr Roger Liang, Prof Darryl Knight, Dr Nathan Bartlett, A/P Christopher Grainge |
| Scheme | Strategic Pilot Grant |
| Role | Lead |
| Funding Start | 2017 |
| Funding Finish | 2018 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
20152 grants / $31,000
Improving the effectiveness of a new treatment for acute myeloid leukaemia (AML)$25,000
Funding body: Hunter Medical Research Institute
| Funding body | Hunter Medical Research Institute |
|---|---|
| Project Team | Doctor Kathryn Skelding, Doctor Mengna Chi, Associate Professor Nikki Verrills, Doctor Roger Liang |
| Scheme | Project Grant |
| Role | Investigator |
| Funding Start | 2015 |
| Funding Finish | 2015 |
| GNo | G1600224 |
| Type Of Funding | Grant - Aust Non Government |
| Category | 3AFG |
| UON | Y |
A supramolecular platform toward mitochondria-targeted nanomedicines$6,000
Funding body: Faculty of Health and Medicine, University of Newcastle
| Funding body | Faculty of Health and Medicine, University of Newcastle |
|---|---|
| Project Team | Dr Roger Liang |
| Scheme | Faculty Pilot Grant |
| Role | Lead |
| Funding Start | 2015 |
| Funding Finish | 2016 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
20141 grants / $1,500
4th Annual World Congress of Nanoscience and Technology, Qingdao, P.R.China, 23 - 31 October 2014$1,500
Funding body: University of Newcastle - Faculty of Health and Medicine
| Funding body | University of Newcastle - Faculty of Health and Medicine |
|---|---|
| Project Team | Doctor Roger Liang |
| Scheme | Travel Grant |
| Role | Lead |
| Funding Start | 2014 |
| Funding Finish | 2014 |
| GNo | G1400985 |
| Type Of Funding | Internal |
| Category | INTE |
| UON | Y |
20121 grants / $45,000
Novel biomaterials and drug delivery $45,000
Funding body: The Faculty of Health Science / The University of Newcastle / Australia
| Funding body | The Faculty of Health Science / The University of Newcastle / Australia |
|---|---|
| Project Team | Dr Roger Liang |
| Scheme | Startup funding |
| Role | Lead |
| Funding Start | 2012 |
| Funding Finish | 2013 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
Research Supervision
Number of supervisions
Current Supervision
| Commenced | Level of Study | Research Title | Program | Supervisor Type |
|---|---|---|---|---|
| 2019 | Honours | Microfluidic synthesis of functional nanoparticles for biomedical applications | Pharmacy, The University of Newcastle | Principal Supervisor |
| 2017 | PhD | Development of a Novel Injectable Chemical Agent for the Sterilisation of Cats and Dogs | PhD (Biological Sciences), Faculty of Science, The University of Newcastle | Co-Supervisor |
| 2016 | PhD | Development of Epithelial Targeted Nanoparticles for Asthma Therapy | PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle | Principal Supervisor |
Past Supervision
| Year | Level of Study | Research Title | Program | Supervisor Type |
|---|---|---|---|---|
| 2017 | PhD | Multifunctional Nanomedicines Based on Albumin for Targeted Breast Cancer Therapy | PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle | Principal Supervisor |
Dr Roger Liang
Position
Senior Lecturer
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine
Focus area
Pharmacy and Experimental Pharmacology
Contact Details
| roger.liang@newcastle.edu.au | |
| Phone | (02) 4985 4959 |
| Fax | (02) 4921 7903 |
Office
| Room | MS117 |
|---|---|
| Building | Medical Science Building |
| Location | Callaghan University Drive Callaghan, NSW 2308 Australia |
Connect with me
